Clinical Trial Update: Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study [Phase 2]

View source ↗

Summary

Phase II exploratory trial evaluating adjuvant treatment of submassive pulmonary embolism with drotrecogin alfa activated; the study has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Embolism

Drugs mentioned

• Drotrecogin alfa (activated) (drotrecogin alfa (activated))

Snippet

Sponsor: Eli Lilly and Company | Conditions: Submassive Pulmonary Embolism | Phase 2 | Status: COMPLETED | Results posted: 2009-06-17